Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N‐activating mutation
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2021-06, Vol.68 (6), p.e28916-n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 6 |
| container_start_page | e28916 |
| container_title | Pediatric blood & cancer |
| container_volume | 68 |
| creator | Harvey, Melissa Irwin, Meredith S. Armstrong, Linlea Seath, Kim Young, Sean Gershony, Sharon Deyell, Rebecca J. |
| description | |
| doi_str_mv | 10.1002/pbc.28916 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2484151425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2484151425</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-d2eeb6ef6642b228df209dd27fb0e06b186191b1cb0d5e1054f60a0c3684cc93</originalsourceid><addsrcrecordid>eNp1kb9O5DAQhy0E4s_eFbwAskTDFQseJ3aSElbcHdIKKOgj23HAkNjBdkBLhcQL8Iz3JOdlgQKJakaabz7N6IfQLpBDIIQeDVId0rICvoa2geVsyggU6589qbbQTgi3CeWElZtoK8sYzVhWbKOXmTdPLhprJPY6DM4GjY3FAls9eic7EaLrBR5ENNpG_GjiTRqqxEUTx2icFR3uXRBGYWHFsFxIbbfoh5vl4p2xIinPAApy_u_5VahoHpLMXuN-jGIp-IE2WtEF_fO9TtDV79Or2d_p_OLP2ex4PlXpVj5tqNaS65bznEpKy6alpGoaWrSSaMIllBwqkKAkaZgGwvKWE0FUxstcqSqboIOVdvDuftQh1r0JSnedsNqNoaZ5mQODnLKE7n9Bb93o06eJYsArBkVWJOrXilLeheB1Ww_e9MIvaiD1Mpg6BVO_BZPYvXfjKHvdfJIfSSTgaAU8mk4vvjfVlyezlfI_F3-aEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2516951737</pqid></control><display><type>article</type><title>Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N‐activating mutation</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Harvey, Melissa ; Irwin, Meredith S. ; Armstrong, Linlea ; Seath, Kim ; Young, Sean ; Gershony, Sharon ; Deyell, Rebecca J.</creator><creatorcontrib>Harvey, Melissa ; Irwin, Meredith S. ; Armstrong, Linlea ; Seath, Kim ; Young, Sean ; Gershony, Sharon ; Deyell, Rebecca J.</creatorcontrib><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.28916</identifier><identifier>PMID: 33523537</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Anaplastic Lymphoma Kinase - genetics ; Crizotinib ; Hematology ; Humans ; Inhibitor drugs ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Mutation ; Neuroblastoma ; Neuroblastoma - drug therapy ; Neuroblastoma - genetics ; Oncology ; Pediatrics ; Protein Kinase Inhibitors ; Protein-tyrosine kinase ; Targeted cancer therapy</subject><ispartof>Pediatric blood & cancer, 2021-06, Vol.68 (6), p.e28916-n/a</ispartof><rights>2021 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-d2eeb6ef6642b228df209dd27fb0e06b186191b1cb0d5e1054f60a0c3684cc93</citedby><cites>FETCH-LOGICAL-c3536-d2eeb6ef6642b228df209dd27fb0e06b186191b1cb0d5e1054f60a0c3684cc93</cites><orcidid>0000-0002-2452-5181 ; 0000-0003-3315-4383 ; 0000-0002-2878-659X ; 0000-0002-8191-6429</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.28916$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.28916$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33523537$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harvey, Melissa</creatorcontrib><creatorcontrib>Irwin, Meredith S.</creatorcontrib><creatorcontrib>Armstrong, Linlea</creatorcontrib><creatorcontrib>Seath, Kim</creatorcontrib><creatorcontrib>Young, Sean</creatorcontrib><creatorcontrib>Gershony, Sharon</creatorcontrib><creatorcontrib>Deyell, Rebecca J.</creatorcontrib><title>Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N‐activating mutation</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><subject>Anaplastic Lymphoma Kinase - genetics</subject><subject>Crizotinib</subject><subject>Hematology</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Mutation</subject><subject>Neuroblastoma</subject><subject>Neuroblastoma - drug therapy</subject><subject>Neuroblastoma - genetics</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Protein Kinase Inhibitors</subject><subject>Protein-tyrosine kinase</subject><subject>Targeted cancer therapy</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kb9O5DAQhy0E4s_eFbwAskTDFQseJ3aSElbcHdIKKOgj23HAkNjBdkBLhcQL8Iz3JOdlgQKJakaabz7N6IfQLpBDIIQeDVId0rICvoa2geVsyggU6589qbbQTgi3CeWElZtoK8sYzVhWbKOXmTdPLhprJPY6DM4GjY3FAls9eic7EaLrBR5ENNpG_GjiTRqqxEUTx2icFR3uXRBGYWHFsFxIbbfoh5vl4p2xIinPAApy_u_5VahoHpLMXuN-jGIp-IE2WtEF_fO9TtDV79Or2d_p_OLP2ex4PlXpVj5tqNaS65bznEpKy6alpGoaWrSSaMIllBwqkKAkaZgGwvKWE0FUxstcqSqboIOVdvDuftQh1r0JSnedsNqNoaZ5mQODnLKE7n9Bb93o06eJYsArBkVWJOrXilLeheB1Ww_e9MIvaiD1Mpg6BVO_BZPYvXfjKHvdfJIfSSTgaAU8mk4vvjfVlyezlfI_F3-aEQ</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Harvey, Melissa</creator><creator>Irwin, Meredith S.</creator><creator>Armstrong, Linlea</creator><creator>Seath, Kim</creator><creator>Young, Sean</creator><creator>Gershony, Sharon</creator><creator>Deyell, Rebecca J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2452-5181</orcidid><orcidid>https://orcid.org/0000-0003-3315-4383</orcidid><orcidid>https://orcid.org/0000-0002-2878-659X</orcidid><orcidid>https://orcid.org/0000-0002-8191-6429</orcidid></search><sort><creationdate>202106</creationdate><title>Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N‐activating mutation</title><author>Harvey, Melissa ; Irwin, Meredith S. ; Armstrong, Linlea ; Seath, Kim ; Young, Sean ; Gershony, Sharon ; Deyell, Rebecca J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-d2eeb6ef6642b228df209dd27fb0e06b186191b1cb0d5e1054f60a0c3684cc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anaplastic Lymphoma Kinase - genetics</topic><topic>Crizotinib</topic><topic>Hematology</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Mutation</topic><topic>Neuroblastoma</topic><topic>Neuroblastoma - drug therapy</topic><topic>Neuroblastoma - genetics</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Protein Kinase Inhibitors</topic><topic>Protein-tyrosine kinase</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harvey, Melissa</creatorcontrib><creatorcontrib>Irwin, Meredith S.</creatorcontrib><creatorcontrib>Armstrong, Linlea</creatorcontrib><creatorcontrib>Seath, Kim</creatorcontrib><creatorcontrib>Young, Sean</creatorcontrib><creatorcontrib>Gershony, Sharon</creatorcontrib><creatorcontrib>Deyell, Rebecca J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harvey, Melissa</au><au>Irwin, Meredith S.</au><au>Armstrong, Linlea</au><au>Seath, Kim</au><au>Young, Sean</au><au>Gershony, Sharon</au><au>Deyell, Rebecca J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N‐activating mutation</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2021-06</date><risdate>2021</risdate><volume>68</volume><issue>6</issue><spage>e28916</spage><epage>n/a</epage><pages>e28916-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33523537</pmid><doi>10.1002/pbc.28916</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-2452-5181</orcidid><orcidid>https://orcid.org/0000-0003-3315-4383</orcidid><orcidid>https://orcid.org/0000-0002-2878-659X</orcidid><orcidid>https://orcid.org/0000-0002-8191-6429</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2021-06, Vol.68 (6), p.e28916-n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2484151425 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anaplastic Lymphoma Kinase - genetics Crizotinib Hematology Humans Inhibitor drugs Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Neuroblastoma Neuroblastoma - drug therapy Neuroblastoma - genetics Oncology Pediatrics Protein Kinase Inhibitors Protein-tyrosine kinase Targeted cancer therapy |
| title | Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N‐activating mutation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A22%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crizotinib%20response%20in%20a%20neuroblastoma%20patient%20with%20a%20constitutional%20mosaic%20anaplastic%20lymphoma%20kinase%20I1170N%E2%80%90activating%20mutation&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Harvey,%20Melissa&rft.date=2021-06&rft.volume=68&rft.issue=6&rft.spage=e28916&rft.epage=n/a&rft.pages=e28916-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.28916&rft_dat=%3Cproquest_cross%3E2484151425%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2516951737&rft_id=info:pmid/33523537&rfr_iscdi=true |